TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03081884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC PET-CT Imaging
Description: Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection.
Study: NCT01223729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine
Description: 2 g acetyl-L carnitine twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice per day
Study: NCT02197663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture(44mm in length and 32-gauge)
Description: The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: acupuncture(44mm in length and 32-gauge)
Description: The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
Study: NCT00983320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: flexible dosage (50 to 300 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00666406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)
Description: Infusion of 50 +/- 5 IU/kg bodyweight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Factor VIII (rAHF)
Description: Infusion of 50 +/- 5 IU/kg bodyweight
Study: NCT01368653

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment+practice quitting
Description: This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very low nicotine cigarettes
Description: This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
Study: NCT03196453

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: probiotic and/or placebo intervention in toddlers

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: probiotic and/or placebo intervention in toddlers

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: probiotic and/or placebo intervention in toddlers
Study: NCT04363645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicontext (MC) approach
Description: The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
Study: NCT02167334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positive pressure ventilation
Description: Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygenation with simple breathing mask
Description: Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
Study: NCT01328483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrapartum Oropharyngeal Suctioning
Description: After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
Study: NCT03187249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 12 weeks cognitive-behavioral lessons, once a week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation Therapy
Description: 12 weeks pulmonary rehabilitation exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Therapy
Description: cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
Study: NCT02319304

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
Description: see arm description

Intervention type: RADIATION
Group type: OTHER
Intervention: Low dose fractionated radiation therapy (LDFRT)
Description: see arm description
Study: NCT01019824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralfinamide
Description: Ralfinamide Oral Tablets, 160 or 320 mg per day
Study: NCT02496182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet only with the excipients of the Pirfenidone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
Study: NCT01019824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralfinamide
Description: Ralfinamide Oral Tablets, 160 or 320 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ralfinamide
Description: Ralfinamide Oral Tablets, 160 or 320 mg per day
Study: NCT02077556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell \< 4000/mcL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
Study: NCT02500953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325
Study: NCT02077556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
Study: NCT02135445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Degarelix injection
Study: NCT03202056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry needling
Description: Sham Dry needling use a non-penetrating acupuncture needle
Study: NCT02010086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy
Description: Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Treatment
Description: In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
Study: NCT03573154

Intervention type: OTHER
Group type: OTHER
Intervention: administration of the liquid 1 and then the liquid 2
Description: The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second

Intervention type: OTHER
Group type: OTHER
Intervention: administration of the liquid 2 and then the liquid 1
Description: The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
Study: NCT00620386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils
Description: Endotracheal intubation using Bonfils Intubating Fiberscope
Study: NCT02500953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325
Study: NCT03778307

Intervention type: BEHAVIORAL
Intervention: Psychophysiological fear conditioning and extinction task
Description: Behavioral task to assess psychophysiological measures of fear

Intervention type: BEHAVIORAL
Intervention: Psychophysiological fear conditioning and extinction task
Description: Behavioral task to assess psychophysiological measures of fear
Study: NCT00620386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Endotracheal intubation using Macintosh laryngoscopy
Study: NCT04104178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00857571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg Suspension
Description: Single oral dose of 150 mg of PF-02413873 suspension
Study: NCT03778307

Intervention type: BEHAVIORAL
Intervention: Eyetracking task
Description: Behavioral task to assess dysphoria-relevant attention allocation

Intervention type: BEHAVIORAL
Intervention: Eyetracking task
Description: Behavioral task to assess dysphoria-relevant attention allocation
Study: NCT00857571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Suspension
Description: Single oral dose of 30 mg of PF-02413873 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Suspension
Description: Single oral dose of 400 mg of PF-02413873 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Suspension
Description: Single oral dose of 5 mg of PF-02413873 suspension
Study: NCT02500953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325
Study: NCT04560049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: application of silver nitrate to sinus tract

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenol
Description: phenolisation of sinus tract
Study: NCT02500953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03461120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental continuous peripheral nerve blocks
Description: Bupivacaine 0.3% \[or ropivacaine 0.5%\] infusions for 7 days via femoral and sciatic perineural catheters
Study: NCT02500953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00857571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg Suspension
Description: Single oral dose of 750 mg of PF-02413873 suspension
Study: NCT03461120

Intervention type: DRUG
Group type: OTHER
Intervention: Control continuous peripheral nerve blocks
Description: Bupivacaine 0.1% \[or ropivacaine 0.2%\] infusions for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
Study: NCT03736889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab (BGB-A317)
Description: Anti-PD-1 Antibody
Study: NCT00857571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg Tablet
Description: Single oral dose of 150 mg of PF-02413873 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Tablet
Description: Single oral dose of 30 mg of PF-02413873 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Tablet
Description: Single oral dose of 400 mg of PF-02413873 tablets
Study: NCT01672255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
Study: NCT03188887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticotherapy
Description: 3 IV pulses steroids followed by oral steroids for 4 months
Study: NCT00857571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Tablet
Description: Single oral dose of 5 mg of PF-02413873 tablets
Study: NCT03188887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)
Description: treatment with Renin angiotensin system (RAS) blockade or SGLT2i

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)
Description: treatment with Renin angiotensin system (RAS) blockade or SGLT2i
Study: NCT02004834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: Comparing: 0,5% levobupivacaine with 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: Comparing: 0,5% levobupivacaine with 2% lidocaine
Study: NCT01456325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
Study: NCT04173000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mehealth for ADHD software with medication continuity tools
Description: Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
Study: NCT01456325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMab)
Description: Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
Study: NCT01277939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Description: Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
Study: NCT04173000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mehealth for ADHD software without medication continuity tools
Description: The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems.
Study: NCT03471637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy
Description: Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]
Study: NCT00455104

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational, voluntary registry.
Study: NCT00286832

Intervention type: PROCEDURE
Intervention: PET scan
Description: One extra PET scan after 1 cycle of treatment.
Study: NCT04070300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval exercise
Description: Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
Study: NCT01801787

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: active vs. sham tDCS left hemisphere
Study: NCT01838707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine HCL @ 4-5 ml/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
Study: NCT02830893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARA
Description: Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.